• Donor Login
  • Contact Us
  • Breakthrough T1D
T1D Fund: A Breakthrough T1D Venture
  • About
  • Investment Strategy
  • Portfolio
  • Our Team
  • News
  • Donor Login
  • Get in Touch

The T1D Fund Team

  • The Team
  • Board of Directors
  • Investment Committee
  • Partners and Advisors
Elizabeth Mily Chief Executive Officer
Sylvia Tobé, PhD Managing Director
Lucio Iannone, PhD Managing Director
Dan McNamara Head of Strategy and Industry Engagement
Eric Shen Chief of Staff
Sean O'Connor, PhD Principal
Daniel Flicker, PhD Senior Associate
Peyman Hosseinchi, PhD Senior Associate
Valerie Su, PhD Associate
Morgan Janes, PhD Associate
Yash Malliwal Senior Analyst
Matt Williams Director of Operations
Jay Eastman, Chair
Amy Raskin, Vice Chair
Karen Jordan
Aaron J. Kowalski
Ellen Leake
David Nelms
Jennifer Ross
Elizabeth Mily, Chair
Jay Eastman
Amy Raskin
Tim Clark
Brady Bohrmann
Lucio Iannone
Sylvia Tobé
Sean Doherty Founder & Former T1D Fund Board Chair
Peter Gottlieb, MD Professor of Pediatrics and Medicine at the Barbara Davis Center at the University of Colorado School of Medicine.
Teresa Foy, PhD Immunologist and Biopharmaceutical R&D Leader
Frank Martin, PhD Biotechnology Venture Advisor

About The T1D Fund

Launched in 2016, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through equity investments. The Fund co-invests with venture capital and biopharma in support of early-stage companies pursuing disease-modifying therapies and potential cures for T1D. A core element of our mission is to rapidly advance promising therapies through development and ultimately regulatory approval. The Fund works in close partnership with Breakthrough T1D (formerly JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust—two of the leading global organizations committed to supporting the T1D community and to advancing T1D research and innovation. Led by a deeply experienced team of healthcare and investing professionals, the Fund leverages its vast research, clinical, regulatory, and medical affairs network on behalf of its portfolio companies. Capitalized through philanthropic dollars, the Fund makes investments in biotech companies and recycles returns into new investments, thereby extending the impact of its donors’ contributions.

  • About
  • Investment
    Strategy
  • Portfolio
  • Our Team
  • News
  • Privacy Policy
Contact Us

For more information email us at info@t1dfund.org

T1D Fund: A Breakthrough T1D Venture

© Copyright 2025. All Rights Reserved